News

Commission guidelines on prohibited AI practices

Published on | 3 months ago

Programmes Horizon Europe Digital Europe

The European Commission has published guidelines on prohibited artificial intelligence (AI) practices, as defined by the EU AI Act. The guidelines provide an overview of AI practices that are considered unacceptable due to their potential risks to European values and fundamental rights. 

The AI Act, which aims to promote innovation while ensuring high levels of health, safety, and fundamental rights protection, classifies AI systems into different risk categories, including prohibited, high-risk, and those subject to transparency obligations. The guidelines specifically address practices such as harmful manipulation, social scoring, and real-time remote biometric identification.

The guidelines aim to provide a consistent, effective and uniform application of the AI Act. They are non-binding, with authoritative interpretations reserved for the Court of Justice of the European Union (CJEU). The guidelines provide legal explanations and practical examples to help stakeholders understand and comply with the AI Act's requirements.

It is important to note that at this stage, the Commission has approved the draft guidelines, but not yet formally adopted them.

The guidelines can be found on the Commission website.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1601 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.